Entries |
Document | Title | Date |
20080200657 | Mutant of Granulocyte-Colony Stimulating Factor (G-Csf) and Chemically Conjugated Polypeptide Thereof - Provided are mutants of human granulocyte-colony stimulating factor (G-CSF) designed for specific chemical conjugation, and chemical conjugates thereof for use as an adjuvant in the treatment of cancer. The present invention provides a mutant of a G-CSF in which a threonine (Thr) residue at position 133 of G-CSF comprising the amino acid sequence identified in SEQ ID NO: 1 is substituted with a cysteine (Cys) residue. In addition, the invention provides a mutant of a G-CSF in which a cysteine (Cys) residue is inserted between a glycine (Gly) residue at position 135 and an alanine (Ala) residue at position 136 of G-CSF. Further, the invention provides a chemically conjugated mutant G-CSF to which biocompatible polymer such as polyethylene glycol (PEG) was attached at the cysteine residue, which was introduced by the substitution or insertion mutation, increasing its in vivo retention time without reducing in vivo biological activity due to the conjugation with the biocompatible polymer, thereby ultimately extending the in vivo biological activity. | 08-21-2008 |
20080234471 | Fucosyl transferase gene - A DNA molecule is provided which comprises a sequence according to SEQ ID NO: 1 having an open reading frame from base pair 211 to base pair 1740 or having at least 50% homology to the above-indicated sequence, or hybridizing with the above-indicated sequence under stringent conditions, or comprising a sequence which has degenerated to the above-indicated DNA sequence because of the genetic code, the sequence coding for a plant protein having fucosyltransferase activity or being complementary thereto. | 09-25-2008 |
20080242846 | O-LINKED GLYCOSYLATION OF PEPTIDES - The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response. | 10-02-2008 |
20080281083 | Antigen of the Pm-2 Antibody and Use Thereof - A polypeptide, which is expressed on the cell surface as a membrane-bound protein, is glycolyzed at one or more points (i.e., membrane glycoprotein) and has an amino acid sequence that corresponds partially or completely to that of the integrin binding protein p80 (accession #AJ131720) or REV1 (accession #AF206019.) The membrane glycoprotein, is expressed by neoplastic cells and not by non-neoplastic cells as an antigen, specifically binds the human monoclonal antibody PM-2 (DSM number: DSM ACC2600) and is, in addition, N-glycosidically and O-glucosidically linked. A related method is provided for the isolation or production of the antigen and for the use of the latter for producing a medicament for immunization. The isolated antigen can also be used to identify medicaments with an apoptotic cell-proliferation inhibiting action. The membrane glycoprotein can also be used as a tumor marker. | 11-13-2008 |
20080281084 | Formulation, Solubilization, Purification, and Refolding of Tissue Factor Pathway Inhibitor - Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations. | 11-13-2008 |
20080312423 | Preparation of Metal Ion-Lactoferrin - The present invention provides processes for preparing metal ion-lactoferrin by first immobilising lactoferrin in a lactoferrin-binding matrix and then contacting the immobilised lactoferrin with a source of metal ions, preferably a milk composition containing metal ions. A preferred product of the process is iron-lactoferrin. | 12-18-2008 |
20090005540 | Method For Removing Sialic Acid and Method For Producing Asialoerythropoietin - The object is to provide a method for removing a sialic acid that can be carried out simply at a low cost and a method for producing asialoerythropoietin using the same. The method for removing a sialic acid according to the present invention includes an acidifying and heating process of acidifying and heating a solution containing erythropoietin so as to remove a sialic acid bonded to an erythropoietin molecule. Further, the method for producing asialoerythropoietin according to the present invention includes a sialic acid removing process of removing a sialic acid bonded to an erythropoietin molecule by the method for removing a sialic acid according to the present invention. | 01-01-2009 |
20090012273 | Method of Regenerating Elastic Fiber with the Use of Dance or Factor Enhancing the Expression Thereof - The present invention provides a technique for conveniently and efficiently regenerating elastic fiber retaining a normal structure, and a technique enabling preparation of an artificial tissue comprising elastic fiber (for example, artificial skin, artificial blood vessels) that can be transplanted to humans. Specifically, the invention provides a method of producing elastic fiber, comprising culturing (for example, culturing in serum-free medium) cells having the capability of regenerating elastic fiber in the presence of DANCE and/or fibulin-4; artificial elastic fiber comprising DANCE and/or fibulin-4; an elastic fiber regenerating agent; a serum-free medium comprising DANCE and/or fibulin-4; and cells having the capability of regenerating elastic fiber, transfected with at least one of a DANCE expression vector, a fibulin-4 expression vector and a DANCE inducing factor expression vector, and the like. | 01-08-2009 |
20090105462 | Glycosylated erythropoietin - The invention relates to erythropoietin having certain O-linked and/or N-linked oligosaccharide structures. | 04-23-2009 |
20090176970 | Preparation of Thiosugars and Their Use - A process for the preparation of a thiosaccharide represented by Saccharide-S-H wherein Saccharide comprises at least 4 sugar units, comprises subjecting a corresponding compound of the formula (P)Saccharide-S-(P) wherein (P) represents an O- or S-protecting group(s), to Birch reduction. | 07-09-2009 |
20090275739 | Purification of Glycopeptides - A novel and improved method for purification of glycopeptides, especially glycopeptide antibiotics. The method comprises contacting a solution of the glycopeptide to an ion exchange chromatography material. The product of this method has a surprisingly high purity. | 11-05-2009 |
20090292114 | METHOD FOR THE PURIFICATION OF ALPHA-1-ANTITRYPSIN - The invention relates to methods for the isolation of AAT from solutions containing albumin and AAT using at least two separate metal chelate chromatography steps. The product may be further purified and/or subjected to one or more virus inactivation or reduction steps. The isolated AAT may then be formulated for pharmaceutical use. | 11-26-2009 |
20090299040 | MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS - The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 12-03-2009 |
20100016561 | N-Acetylglucosaminyltransferase III Expression in Lower Eukaryotes - The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIII activity, which produce bisected N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained. | 01-21-2010 |
20100036103 | Method for producing apoprotein - A method and an apparatus for producing an apoprotein with which the apoprotein can be efficiently produced from a protein associated with cofactors such as metal ions. The method includes the step of adding an acid to a solution which contains a holoprotein, which is associated with a cofactor which is to be released under acidic conditions, and concentrating the solution with an ultrafiltration membrane. Accordingly, an apoprotein, which has released its cofactor, is produced, and the released cofactor is removed through the membrane along with the acid without reassociating with the apoprotein. | 02-11-2010 |
20100145032 | NOVEL CARBOHYDRATE PROFILE COMPOSITIONS FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies. | 06-10-2010 |
20100168401 | Method, composition and kit for detecting phosphatidylserine (PS) on cell membranes - A method, composition and kit for detecting the presence of a phospholipid, such as phosphatidylserine, on a cell membrane is provided. A binding agent including lactadherin, a fragment of lactadherin, a functional equivalent of lactadherin, or a functional equivalent of a fragment of lactadherin, is used to detect the presence of any phospholipid. | 07-01-2010 |
20100184961 | METHODS AND COMPOSITIONS RELATED TO CHROMATIN-ASSOCIATED PROTEINS AND OTHER FACTORS - Chromatin-associated proteins and other factors and their related methods and compositions are isolated and identified. | 07-22-2010 |
20100234580 | Process for Producing Proteoglycan - An efficient low-cost method of proteoglycan recovery from natural resources. There is provided a process for producing proteoglycan, comprising the steps of immersing a biological sample containing proteoglycan in an alkali solution of 0.0025 to 0.1 N and recovering the solution after the immersion. As compared with the conventional extraction method, proteoglycan can be recovered in unaltered undecomposed form easily within a short period of time, thereby attaining substantial reduction of proteoglycan production cost. Further, proteoglycan highly useful in industry can be recovered from wasted portions of fin, feather, mammal, etc. having mainly been discarded, thereby contributing toward effective utilization of industrial waste and reduction of the volume of industrial waste per se. | 09-16-2010 |
20100273992 | METHOD FOR THE PRODUCTION OF AN IMMUNOSTIMULATING MUCIN (MUC1) - The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumours. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumours. | 10-28-2010 |
20100305308 | Lactoferrin - A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the mixture. | 12-02-2010 |
20110021760 | CRYSTALLINE VAP-1 AND USES THEREOF - The present invention relates to crystalline vascular adhesion protein-1 (VAP-1) and in particular to methods for the use of structural information of crystalline human VAP-1 for ligand and/or inhibitor identification, design and production, as well as screening assays for detections of same. The invention further relates to inhibitors identified by the assays according to the present invention. | 01-27-2011 |
20110046356 | POST-TRANSLATIONAL MODIFICATIONS AND CLOSTRIDIAL NEUROTOXINS - The present invention discloses modified neurotoxins with altered biological persistence. In one embodiment, the modified neurotoxins are derived from Clostridial botulinum toxins. Such modified neurotoxins may be employed in treating various conditions, including but not limited to muscular disorders, hyperhidrosis, and pain. | 02-24-2011 |
20110071279 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 03-24-2011 |
20110144314 | METHOD FOR SELECTIVELY EXTRACTING MEMBRANE PROTEINS USING CALIXARENES - The present invention relates to a method for selectively extracting membrane proteins using at least one calixarene of formula (I). The use of calixarenes in the method according to the invention enables the selective solubilization of the membrane proteins while preserving the three-dimensional structure that is essential to the enzymatic activity thereof. | 06-16-2011 |
20110196133 | GRIFOLA-DERIVED LOW-MOLECULAR-WEIGHT SUBSTANCE HAVING IMMUNOPOTENTIATING ACTIVITY AND ANTITUMOR ACTIVITY - It is an objective of the present invention to develop a | 08-11-2011 |
20110224409 | SIALIC ACID DERIVATIVES - An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids. | 09-15-2011 |
20110237781 | METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR - Purification of α-1 proteinase inhibitor (α-1 PI) from solutions comprising α-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of α-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising α-1 PI, such as human plasma, followed by anion exchange resin chromatography prior to HIC. Further purification may be accomplished by an optional cation exchange chromatography subsequent to anion exchange chromatography but prior to HIC. Some embodiments of the invention also include virus removal and/or inactivation by methods such as nano filtration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods. | 09-29-2011 |
20110237782 | METHODS FOR GLYCO-ENGINEERING PLANT CELLS FOR CONTROLLED HUMAN O-GLYCOSYLATION - This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon α2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation. Introduction of O-glycosylation into plant cells requires i) that wild-type plant cells do not modify the target peptide substrates and ii) that the appropriate enzymes and substrates are introduced into of plant cells such that O-glycosylation in the secretory pathway proceed and the glycosylated peptide substrates are preferentially exported to the exterior of the cell or accumulated in the cell. In this invention i) the integrity of transiently and stably expressed ‘mucin’ type target peptides in plants cells has been determined and ii) mucin-type O-glycosylation has been established in plants by transient and stable introduction of a | 09-29-2011 |
20110257376 | GLYCOPROTEOMIC PROBES FOR FLUORESCENT IMAGING OF FUCOSYLATED GLYCANS IN VIVO - Methods are provided for labeling cellular glycans bearing azide groups via fluorescent labeling comprising Cu(I)-catalyzed [3+2] cycloaddition of a probe comprising alkynyl group. Generation of fluorescent probes from a nonfluorescent precursor, 4-ethynyl-N-ethyl-1,8-naphthalimide, by Cu(I)-catalyzed [3+2] cycloaddition of the alkyne group of the probe to an azido-modified sugar are provided. Incorporation of azido-containing fucose analog into glycoconjugates via the fucose salvage pathway are disclosed. Fluorescent visualization of fucosylated cells by flow cytometry of cells treated with 6-azidofucose labeled with click-activated fluorogenic probe or biotinylated alkyne is disclosed. Visualization of intracellular location of fucosylated glycoconjugates by fluorescence microscopy are disclosed. | 10-20-2011 |
20110269943 | RADIOLABELED ANNEXINS - Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided. | 11-03-2011 |
20120016110 | METHOD OF IMMOBILIZING AND STRETCHING A NUCLEIC ACID ON A SUBSTRATE - The present invention relates to a method of immobilizing and stretching a nucleic acid on a silicon substrate, to nucleic acids and substrates prepared according to this method, to uses of the method and to uses of the nucleic acid and the substrate. | 01-19-2012 |
20120029173 | ATTENUATED SALMONELLA ENTERICA SEROVAR PARATYPHI A AND USES THEREOF - The present invention is drawn to a live, attenuated | 02-02-2012 |
20120029174 | METHODS FOR PRODUCING SUBSTANTIALLY HOMOGENEOUS HYBRID OR COMPLEX N-GLYCANS IN METHYLOTROPHIC YEASTS - The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step. | 02-02-2012 |
20120041182 | Water Soluble Cholesterol Derivatives - Four novel water soluble cholesterol derivative compounds are disclosed. These compounds have various applications in studies of membrane proteins, including drug screening and studies of receptor stability and folding. In one aspect the water soluble cholesterol derivatives disclosed may be used to replace cholesterol in micelle-solubilized membrane protein preparations. | 02-16-2012 |
20120077965 | NON-AQUEOUS SYNTHESIS OF POLYSACCHARIDE-PROTEIN CONJUGATES FOR VACCINES - The invention is a novel chemical coupling methodology for the synthesis of a stable polysaccharide-protein conjugates as the immunogenic component for vaccines. A covalent bond is formed between polysaccharide and protein in the dry state in the absence of water and oxygen. A polysaccharide antigen is covalently linked to the protein by activating the polysaccharide with periodate to introduce aldehyde groups into the polysaccharide, lyophilizing an aqueous mixture of a protein and activated polysaccharide, sealing the dry lyophilized mixture in a vessel under vacuum or inert gas and then incubating the sealed vessel at an elevated temperature. | 03-29-2012 |
20120088906 | Isolation of Phosphoproteins, Glycoproteins and Fragments thereof - The invention provides methods and apparatus for the selective isolation of phosphorylated and glycosylated proteins and their fragments. Metal cation is used to precipitate proteins or protein fragments containing phospho groups and/or glyco groups. The sample preparation method can be used for several types of biological samples, including HeLa cells, food, and human cerebrospinal fluid. The proteins are isolated, recovered and ready for analysis by mass spectrometry or other analytical methods allowing detection limits down to the femtomole level. The method and apparatus are valuable tools in the field of protein analysis and diagnostics. | 04-12-2012 |
20120101263 | METHOD OF PREPARING LOW-IRON LACTOFERRIN - The present invention relates to methods for producing low-iron Lf having improved antimicrobial activity and to a low-iron Lf having improved antimicrobial activity. | 04-26-2012 |
20120136141 | Integrin Heterodimer And A Subunit Thereof - A recombinant or isolated integrin heterodimer comprising a novel subunit α10 in association with a subunit β is described. The integrin or the subunit α10 can be used as a marker or target of various types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit α10 can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines. | 05-31-2012 |
20120214974 | Devices and Methods for the Purification, Isolation, Desalting or Buffer/Solvent Exchange of Substances - A spin column device, which contains a rigid porous filter that retains its shape during centrifugation, chromatography methods using the device to isolate a desired substance, e.g., a biological molecule, from other substances in a mixture, and kits containing the device with one or more reagents for use in the method. | 08-23-2012 |
20120214975 | AAD-1 EVENT DAS-40278-9, RELATED TRANSGENIC CORN LINES, AND EVENT-SPECIFIC IDENTIFICATION THEREOF - The present invention relates to cells for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties. It also relates to methods for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties using said cells and to molecules obtainable by said methods. The present invention further relates to molecules having an artificial glycosylation pattern. | 08-23-2012 |
20120271041 | PRODUCTION OF GLYCOPROTEINS WITH LOW N-GLYCOLYLNEURAMINIC ACID (NEU5GC) CONTENT - The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc. | 10-25-2012 |
20120283420 | Production of Multi-Antennary N-Glycan Structures in Plants - The invention provides methods for producing multi-antennary glycoproteins in plant and plant cells. In particular the invention provides plants comprising a chimeric gene comprising glucosaminyltransferase IV and plants comprising two chimeric genes comprising glucosaminyltransferase IV and V. | 11-08-2012 |
20130018177 | Production of Sialylated N-Glycans in Lower Eukaryotes - The present invention relates to eukaryotic host cells which have been modified to produce sialylated glycoproteins by the heterologous expression of a set of glycosyltransferases, including sialyltransferase and/or trans-sialidase, to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. Novel eukaryotic host cells expressing a CMP-sialic acid biosynthetic pathway for the production of sialylated glycoproteins are also provided. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities (such as those involved in sialylation) to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. | 01-17-2013 |
20130053550 | YEAST STRAINS PRODUCING MAMMALIAN-LIKE COMPLEX N-GLYCANS - Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway. | 02-28-2013 |
20130072667 | USE OF RGM AND ITS MODULATORS - The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system. | 03-21-2013 |
20130144043 | POLYSIALIC ACID DERIVATIVES - A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group. | 06-06-2013 |
20130150564 | Modified FGF-21 Polypeptides and Their Uses - Modified FGF-21 polypeptides and uses thereof are provided. | 06-13-2013 |
20130158239 | HYDROLYSIS OF MANNOSE-1-PHOSPHO-6-MANNOSE LINKAGE TO PHOSPHO-6-MANNOSE - Described herein are methods and genetically engineered cells useful for uncapping a mannose-6-phosphate residue on an oligosaccharide. | 06-20-2013 |
20130172537 | REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS - The present invention relates to process for reducing the endotoxin content of a sample of fermentation broth containing polysialic acid and endotoxin comprising the sequential steps: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12, incubating the solution for a pre-determined time at a pre-determined temperature; and (ii) recovery of PSA, suitably by (iii) passing the sample through an anion-exchange column whereby polysialic acid is absorbed on the ion exchange resin; (iv) washing the column with one washing buffer, whereby polysialic acid remains absorbed on the ion exchange resin; and (v) eluting the polysialic acid from the column using an elution buffer to provide a product solution of polysialic acid having reduced endotoxin content. | 07-04-2013 |
20130197203 | Modified Polysaccharides for Conjugate Vaccines - The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease. | 08-01-2013 |
20130203971 | METHOD FOR PURIFICATION OF COMPLEMENT FACTOR H - A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of:
| 08-08-2013 |
20130225795 | RECOMBINANT CODON OPTIMISED FACTOR H - The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials. | 08-29-2013 |
20130237693 | METHOD FOR PRODUCING HIGH-PURITY SOLUBLE THROMBOMODULIN - The aim of the present invention is to obtain soluble thrombomodulin substantially not containing a denatured product of soluble thrombomodulin that is generated under acidic conditions. A method is provided for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that is generated under acidic conditions, which comprises; subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein said gradient is a salt concentration gradient, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction. | 09-12-2013 |
20130245238 | Fibronectin Binding Domains with Reduced Immunogenicity - Fibronectin type III ( | 09-19-2013 |
20130245239 | PROTEOGLYCAN-BONDED FIBER PRODUCT AND METHOD OF MANUFACTURING SAME - An objective is to provide fiber products having smooth texture and excellent softness, and in addition, excellent durability. A proteoglycan-bonded fiber product including a fiber to which a proteoglycan is covalently bonded is provided. | 09-19-2013 |
20130303736 | METHOD FOR MASS PREPARATION OF PROTEOGLYCAN - An object of the present invention is to efficiently extract proteoglycan from aquatic animal tissues. The method of the present invention is a method for extracting proteoglycan from fish cartilage, comprising the step of (A) heating small pieces of frozen fish cartilage in water. This method of the present invention enables easy extraction of proteoglycan from fish cartilage with very high efficiency. In particular, the method of the present invention enables extraction of high-molecular-weight proteoglycan. Further, since in the method of the present invention, extraction is performed using only water, it ensures safety in the extraction and safety of the resulting proteoglycan product, compared with hitherto known extraction methods using organic solvents or acids/alkali. Furthermore, the cumbersome step of removing organic solvents is not necessary in the method of the present invention. | 11-14-2013 |
20130310546 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation and analyzing the conjugation using 2D NMR analysis. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst. | 11-21-2013 |
20140024812 | ENGINEERED INTRACELLULAR SIALYLATION PATHWAYS - Methods for manipulating carbohydrate processing pathways in cells of interest are provided. Methods are directed at manipulating multiple pathways involved with the sialylation reaction by using recombinant DNA technology and substrate feeding approaches to enable the production of sialylated glycoproteins in cells of interest. These carbohydrate engineering efforts encompass the implementation of new carbohydrate bioassays, the examination of a selection of insect cell lines and the use of bioinformatics to identify gene sequences for critical processing enzymes. The compositions comprise cells of interest producing sialylated glycoproteins. The methods and compositions are useful for heterologous expression of glycoproteins. | 01-23-2014 |
20140066606 | PRODUCTION OF HIGH MANNOSE GLYCOSYLATED PROTEINS STORED IN THE PLASTID OF MICROALGAE - The present invention concerns a transformed microalga producing a protein harboring a “high mannose” pattern of glycosylation in the plastid of the transformed microalga, wherein 1) the transformed microalga has a Chloroplast Endoplasmic Reticulum (CER); 2) the microalga has been transformed with a nucleic acid sequence operatively linked to a promoter, the nucleic acid sequence encoding an amino acid sequence including (i) an amino-terminal bipartite topogenic signal (BTS) sequence composed of at least a signal peptide followed by a transit peptide; and (ii) The sequence of the protein, 3) the xylosyltransferases and fucosyltransferases of the microalga have not been inactivated; 4) the N-acetylglycosyltransferase I of the microalga has not been inactivated, preferably the N-acetylglycosyltranferases II, III, IV, V and VI, mannosidase II and glycosyltransferases of the microalga have not been inactivated. | 03-06-2014 |
20140066607 | METHOD FOR ISOLATING OSTEOPONTIN USING CONCENTRATED FEEDS - The present invention pertains to a method for isolating osteopontin from milk-derived feeds having a high concentration of protein. Particularly, the present method involves the use of a narrow window of pH and specific conductance of the milk-derived feed, which surprisingly has proven to provide a very efficient isolation of osteopontin from chemically complex feeds. | 03-06-2014 |
20140094595 | Protein Scaffolds for Antibody Mimics and Other Binding Proteins - Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands. | 04-03-2014 |
20140148586 | DESIGNING A SOLUBLE FULL-LENGTH HIV-1 GP41 TRIMER - Described herein is a soluble HIV-1 retrovirus transmembrane glycoprotein gp41 trimer (Soc-gp41M-Fd) containing a partial ectodomain and the cytoplasmic domain, that is fused to the small outer capsid (Soc) protein of bacteriophage T4 and the Foldon domain of the bacteriophage T4 fibritin (Fd). The gp41 trimer that has a prehairpin structure could be utilized to understand the mechanism of viral entry and as a candidate for development of HIV-1 vaccines, diagnostics and therapeutics. Other secondary embodiments of the gp41 proteins containing different modifications are also disclosed. According to one embodiment, the gp41 trimer is further attached to a cell penetration peptide (CPP). Methods of producing gp41 trimers are also disclosed. | 05-29-2014 |
20140155585 | HAPTENS OF RISPERIDONE AND PALIPERIDONE - The invention relates to compounds of Formula I, wherein R | 06-05-2014 |
20140275496 | ISOLATION OF FACTOR H FROM FRACTION I PASTE - Among other aspects, the present disclosure provides methods for preparing enriched compositions of plasma-derived Factor H from fractions formed during the manufacturing processes of established plasma-derived therapeutic compositions. Specifically, methods are provided for the isolation of Factor H from Fraction precipitates commonly discarded during the manufacture of commercial IgG therapeutics. Advantageously, the Factor H compositions prepared according to these methods have improved proteolytic profiles and reduced amidolytic activity. | 09-18-2014 |
20140288281 | PRODUCTION OF GLYCOPROTEINS WITH LOW N-GLYCOLYLNEURAMINIC ACID (NEU5GC) CONTENT - The present invention relates to a medium for the cultivation of eukaryotic cells, the medium comprising as (an) additive(s) DMSO, N-acetylmannosamine (NAcMan), N-acetylglucosamine (NAcGlc), or any combination of two or more of these additives, including the combination of NAcMan and NAcGlc. | 09-25-2014 |
20140323699 | METHOD OF DETECTING CANCER BASED ON GLYCAN BIOMARKERS - The present invention provides a method for labeling or detecting a protein with certain glycosyl groups. The methods are particularly useful for detecting cancer cells comprising the detected glycosyl groups. The present invention further provides labeling agents and detection agents, labeled proteins and mixtures, and kits and arrays thereof. | 10-30-2014 |
20140323700 | RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS - The present invention relates to recombinant N-glycosylated proteins, comprising one or more introduced N-glycosylated optimized amino acid sequence(s), nucleic acids encoding these proteins as well as corresponding vectors and host cells. In addition, the present invention is directed to the use of said proteins, nucleic acids, vectors and host cells for preparing medicaments. Furthermore, the present invention provides methods for producing said proteins. | 10-30-2014 |
20140329998 | METHODS FOR MAKING SACCHARIDE-PROTEIN GLYCOCONJUGATES - The invention provides a process for the reductive amination of a carbonyl group at the reducing terminus of a polysaccharide, wherein the reductive amination is carried out at a pH between 4 and 5. The invention also provides a process for preparing a conjugate of a polysaccharide and a carrier molecule, comprising the steps of: (a) coupling the polysaccharide to a linker, to form a polysaccharide-linker compound in which the free terminus of the linker is an ester group; and (b) reacting the ester group with a primary amine group in the carrier molecule, to form a polysaccharide-linker-carrier molecule conjugate in which the linker is coupled to the carrier molecule via an amide linkage. The invention also provides a process for reducing contamination of a polysaccharide-linker compound with unreacted linker, comprising a step of precipitating unreacted linker under aqueous conditions at a pH of less than 5. | 11-06-2014 |
20140336366 | BIOCONJUGATE VACCINES MADE IN PROKARYOTIC CELLS - Provided herein are prokaryotic cells capable of producing bioconjugates comprising glycosylated proteins. Also provided herein are compositions comprising such bioconjugates and/or comprising the saccharide moieties of such bioconjugates, as well as methods of vaccinating subjects using such compositions. | 11-13-2014 |
20140350229 | METHOD FOR PRODUCING SYNTHETIC AMYLOSPHEROID - Provided is a method for producing synthetic amylospheroids efficiently, the method including agitating a liquid containing amyloid β-peptides in the presence of a plasticizer. Amylospheroid refers to an assembly of amyloid β-peptides that selectively can induce cell death of functionally mature neurons. Amylospheroid is considered to play a central role in the development of Alzheimer's disease and dementia with Lewy bodies. | 11-27-2014 |
20140378669 | METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID - Methods for preparing an oligosaccharide—protein carrier immunogenic conjugate or a polysaccharide—protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier. | 12-25-2014 |
20150018535 | GLYCOPROTEIN ENRICHED COMPOSITION AS A FOOD AND/OR FEED ADDITIVE AND/OR AS A THERAPEUTIC AGENT - The present invention relates to glycoprotein enriched compositions and their use in the treatment and/or prevention of disease, more particular gastro-intestinal diseases. The present invention further relates to the use of a glycoprotein enriched composition as a food or feed additive. | 01-15-2015 |
20150031863 | CONJUGATING AMINES - The disclosure provides directly conjugated polysaccharide vaccine molecules and methods related thereto. | 01-29-2015 |
20150038685 | MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 02-05-2015 |
20150051381 | COMBINATORIAL DNA LIBRARY FOR PRODUCING MODIFIED N-GLYCANS IN LOWER EUKARYOTES - The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and express mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man | 02-19-2015 |
20150057439 | METHODS FOR REFOLDING G-CSF FROM INCLUSION BODIES - New methods for the refolding of recombinant granulocyte colony stimulating factor (G-CSF) from inclusion bodies are disclosed. The methods comprise two refolding steps. In particular, the methods comprise the solubilising of G-CSF with a solubilising agent, the oxidative refolding (first refolding step) of G-CSF in the presence of the solubilising agent and an oxidizing agent, the efficient removal of the solubilising agent, and a second refolding step to complete the folding of G-CSF in the absence of the solubilising agent. Various methods are described for the efficient removal of the solubilising agent from partially refolded G-CSF. | 02-26-2015 |
20150087815 | VACCINE COMPOSITIONS - The present disclosure relates to vaccine compositions, particularly KLH-peptide conjugates, and methods of making such compositions. The present disclosure further relates to methods of reducing abnormal cell growth using the compositions described herein. | 03-26-2015 |
20150112047 | ADAPTER MOLECULE CAPABLE OF REVERSIBLY EQUIPPING A FUSION PROTEIN CARRYING AN OLIGOHISTIDINE AFFINITY TAG WITH A FURTHER AFFINITY TAG AND METHODS OF USING THE SAME - Disclosed is a bifunctional adapter molecule comprising two binding moieties A and B, the adapter molecule being capable of reversibly equipping a fusion protein carrying an oligohistidine affinity tag with a further affinity tag, wherein the binding moiety A comprises at least two chelating groups K, wherein each chelating group is capable of binding to a transition metal ion, thereby rendering moiety A capable of binding to an oligohistidine affinity tag, and the binding moiety B is an affinity tag other than an oligohistidine tag. | 04-23-2015 |
20150119558 | CHO-GMT RECOMBINANT PROTEIN EXPRESSION - The present invention provides modified cells for producing proteins with modified glycosylation patterns. Proteins produced in such cells, and the use of such proteins in medicine, and particularly in the treatment of cancer, is also provided. | 04-30-2015 |
20150141626 | REDUCING THE IMMUNOGENICITY OF FUSION PROTEINS - Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy. | 05-21-2015 |
20150344928 | GLYCOSYLATION METHOD - The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated. | 12-03-2015 |
20160032344 | POLYSIALIC ACID, BLOOD GROUP ANTIGENS AND GLYCOPROTEIN EXPRESSION IN PROKARYOTES - The invention described herein generally relates to glycoengineering host cells for the production of glycoproteins for therapeutic use. Host cells are modified to express biosynthetic glycosylation pathways. Novel prokaryotic host cells are engineered to produce N-linked glycoproteins wherein the glycoproteins comprise polysialic acid or blood group antigens. | 02-04-2016 |
20160158345 | PROCESS FOR PREPARING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES - An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of | 06-09-2016 |
20160175430 | MODIFIED POLYSACCHARIDES FOR CONJUGATE VACCINES | 06-23-2016 |
20160376305 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF - Provided herein are methods for the production of native and reconstituted hyaluronan (HA) complexes containing pentraxin-3 (PTX3) and heavy chain 1 (HC1) of inter alpha inhibitor (IαI). Compositions containing the complexes and therapeutic methods using the complexes are provided. Combinations and kits for use in practicing the methods also are provided. | 12-29-2016 |
20160376329 | Glucoprotein for Stimulation of the Immunological System - Several glucoproteins were isolated from the water extract of mushroom | 12-29-2016 |
20160376587 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF - Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects. | 12-29-2016 |